0001171843-26-003495
SEC filingQuantum BioPharma announced a midpoint milestone in its PET imaging study with MGH, with early data supporting the potential of its Lucid-MS candidate for multiple sclerosis.
Quantum BioPharma's press release details progress in a collaborative imaging study with Massachusetts General Hospital. The study has enrolled half of the planned participants, and early PET imaging data using the tracer [18F]3F4AP show promising signal in acute MS lesions. This biomarker could enable direct measurement of demyelination and help evaluate treatments like Lucid-MS, which targets myelin protection. While still early, the milestone supports the company's pipeline without immediate financial impact.